Running title: Ethnic-specific metabolic profiles of GDM

Unique Metabolic Profiles Associate with Gestational Diabetes and Ethnicity in Low and High-Risk Women Living in the UK

Authors: Harriett Fuller^a, Mark Iles^{b,c}, J. Bernadette Moore^a and Michael A. Zulyniak^a*

^a Nutritional Epidemiology Group, School of Food Science and Nutrition, University of Leeds, Woodhouse Lane, Woodhouse, Leeds, LS2 9JT, UK.

^b Leeds Institute of Medical Research, Worsley Building, University of Leeds, Clarendon Way, Woodhouse, Leeds, LS2 9JT, UK.

^c Leeds Institute for Data Analytics, Worsley Building, University of Leeds, Woodhouse, University of Leeds, Clarendon Way, Woodhouse, Leeds, LS2 9JT, UK

*Corresponding Author: Michael Zulyniak. Email. m.a.zulyniak@leeds.ac.uk. Phone +44 113 343 0685

Data described in the manuscript will not be made available but can be requested

through Born in Bradford (https://borninbradford.nhs.uk). Analytic code will be made

available upon request pending approval by the research team.

Funding statement

MZ is currently funded by the Wellcome Trust (217446/Z/19/Z). The Born in Bradford data reported here were supported by a Wellcome Trust infrastructure grant [101597] and the National Institute for Health Research ARC Yorkshire and Humber [NIHR200166]. Funding for the metabolomics analyses has been provided by the US National Institutes of Health [R01 DK10324], the European Research Council (ERC) under the European Union's Seventh Framework Programme [FP7/2007-2013] / ERC grant agreement no 669545 and the MRC via the MRC Integrative Epidemiology Unit Programme [MC_UU_00011/6]

- HF: No conflicts of interest
- MI: No conflicts of interest
- JBM: No conflicts of interest
- MAZ: No conflicts of interest

MI and MAZ designed research. HF and MAZ conducted research. MI and MAZ provided essential materials. HF performed statistical analyses. HF MI JBM and MAZ wrote the paper. MAZ has the primary responsibility for the final content. All authors read and reviewed the final manuscript.

Abbreviations

- ApoA1: Apolipoprotein A1
- BIB: Born in Bradford
- DHA: Docosahexanoic Acid
- FAw3: Total Omega-3
- FAw6: Total Omega-6
- GDM: Gestational Diabetes Mellitus
- GRM: Glycolysis Related Metabolites
- HDL-C: High Density Lipoprotein Cholesterol
- HD2L-C: High Density Lipoprotein-2 Cholesterol
- IQR: Inter Quartile Range
- LDL_D: Diameter of Low Density Lipoprotein
- LPS: Lipoprotein Particle Size
- MSEP: Mean Square Error of Prediction
- MFA: Monounsaturated Fatty Acids
- MW: Mann-Whitney

- NHS: National Health Service
- PCA: Principal Component Analyses
- OGTT: Oral Glucose Tolerance Test
- oPLSDA: Orthogonal Partial Least Squares Discriminatory Analyses
- SAC-H: High Weight South Asian Cases
- SANC-H: High Weight South Asian Non-Cases
- SAC-N: Healthy Weight South Asian Cases
- SANC-N: Healthy Weight South Asian Non-Cases
- PLSDA: Partial Least Squares Discriminatory Analyses
- RMSEE: Root Mean Square Error of Prediction
- ROC: Receiver Operator Curve
- SA: South Asian
- SE: Standard Error
- SFA: Saturated Fatty Acids
- sPLSDA: Sparse Partial Least Squares Discriminatory Analyses
- TCA: Tricarboxylic Acid Cycle
- VIP: Variable Importance in Projection
- VLDL_D: Diameter of Very Low Density Lipoprotein
- WEs: White Europeans
- WEC-N: Healthy Weight White European Cases
- WENC-N: Healthy Weight White European Non-Cases
- WEC-H: High Weight White European Cases
- WENC-H: High Weight White European Non-Cases

4

1 Abstract

2 Background:

- 3 Gestational Diabetes Mellitus (GDM) is the most common global pregnancy
- 4 complication; however, prevalence varies substantially between ethnicities with
- 5 South Asians (SA) experiencing up to 3-times the risk of the disease compared to
- 6 white Europeans (WEs). Factors driving this discrepancy are unclear, although the
- 7 metabolome is of great interest as GDM is known to be characterised by metabolic
- 8 dysregulation.

9 **Objective:**

- 10 This primary aim was to characterise and compare the metabolic profiles of GDM in
- 11 SA and WE women (at < 28 weeks' gestation) from the Born in Bradford (BIB)
- 12 prospective birth cohort in the UK.

13 Methods:

- 14 146 fasting serum metabolites, from 2668 pregnant WE and 2671 pregnant South
- 15 Asian (SA) women (average BMI 26.2 kg/m², average age 27.3 years) were
- 16 analysed using partial least squares discriminatory analyses to characterise GDM
- 17 status. Linear associations between metabolite values and post-oral glucose
- tolerance test measures of dysglycemia (fasting glucose and 2-hour post glucose)
- 19 were also examined.

20 **Results:**

- 21 Seven metabolites associated with GDM status in both ethnicities (variable
- importance in projection (VIP) ≥1), while 6 additional metabolites associated with
- 23 GDM only in WE women. Unique metabolic profiles were observed in healthy weight

5

24	women who later developed GDM, with distinct metabolite patterns identified by
25	ethnicity and BMI status. Of the metabolite values analysed in relation to
26	dysglycemia, lactate, histidine, apolipoprotein A1, HDL cholesterol, HDL2 cholesterol
27	associated with decreased glucose concentration, while DHA and the diameter of
28	very low-density lipoprotein particles (nm) associated with increased glucose
29	concertation in WE women; while in SAs albumin alone associated with decreased
30	glucose concentration.
31	Conclusions
32	This study shows that the metabolic risk profile for GDM differs between WE and SA
33	women enrolled in BiB the UK. This suggests that aetiology of the disease differs
34	between ethnic groups and that ethnic-appropriate prevention strategies may be
35	beneficial.
36	
37	Keywords: GDM, metabolomics, ethnicity, South Asians, pregnancy, maternal
38	health, PLSDA, sPLSDA, personalised nutrition
39	
40	
40	
41	
42	
43	
44	
45	

6

46

47 Introduction

48 During pregnancy, there is a natural increase in catabolism to ensure sufficient 49 energy for the foetus (1, 2). This increase is governed by maternal hormones, 50 beginning as a mild change in insulin sensitivity and progressing through 51 hyperinsulinemia to controlled insulin resistance by the third trimester (2-5). For most 52 pregnancies, these changes are safe and controlled, with insulin sensitivity returning 53 to a healthy state following pregnancy. However, for approximately one in seven 54 pregnancies, insulin resistance exceeds normal "healthy" levels and enters a diabetic 55 state, putting the mother and her growing offspring in danger of short- and long-term 56 health risks (6, 7). This pregnancy-induced state of diabetes, gestational diabetes 57 mellitus (GDM), is a major global health concern with varying prevalence between 58 populations.

59 In Middle Eastern, North Africa, and South Asian countries, GDM prevalence 60 can exceed 20% of pregnancies, whereas in European countries prevalence of GDM 61 is more commonly around 5% (5). Numerous lifestyle, biological, and genetic factors 62 are thought to contribute to this disparity of risk (5, 8). Despite the numerous factors, 63 diet is the mainstay of most prevention and treatment strategies because of its 64 demonstrated efficacy for managing glucose concentrations (9-11). Nonetheless, we 65 and others have demonstrated that the effects of dietary prevention strategies on 66 maternal and offspring health are not generalisable across populations or ethnic 67 groups, with dietary patterns demonstrating varied effects between ethnic groups in 68 relation to both GDM prevention and birth weight (12-15). These data suggest that 69 the metabolism and pathology of GDM may differ across populations, where some 70 ethnic groups have unique metabolic profiles that make them more susceptible to

7

71	GDM (4, 5, 16-18). Specifically, elevated concentrations of alanine, numerous fatty
72	acids (e.g., myristic acid, palmitic acid, palmitoleic acid) and lower amounts of
73	glutamate, proline, and phospholipids in blood have been identified as predictors of
74	GDM risk in early pregnancy (i.e., before 16 weeks) (4), with recent evidence
75	demonstrating significant differences in the abundance of these metabolites between
76	ethnic groups (19). Notably, evidence from Born in Bradford (BiB), a prospective
77	multi-ethnic pregnancy and birth cohort , has demonstrated the need for potentially
78	modified GDM assessment criteria for South Asian (SA) women because of
79	increased risks of delivery complication and newborn macrosomia at significantly
80	lower glucose thresholds, compared to white European (WE) women (20). Indeed,
81	currently the UK's National Health System (NHS), routinely screens all women of
82	South Asian ancestry for GDM while only high-risk WE women are screened (21).
83	As a consequence of this, the Diabetic Pregnancy Study Group called for
84	increased research into the role of the metabolome on GDM in 2018 (22). To date,
85	however, the metabolic drivers of GDM remain unclear with numerous discrepancies
86	within the field, likely due to small, heterogenous cohorts of heterogenous cohorts of
87	varying populations, cultures, and ancestral groups (23). Indeed, only one study has
88	conducted an analysis of individual metabolites and GDM in an ethnic-specific
89	fashion (1). This work investigated univariate associations between numerous
90	metabolites in WE (n = 4072) and SA (n = 4702) women and demonstrated that
91	concentrations of lipoproteins and cholesterols are typically higher in WE women and
92	are stronger predictors of GDM (ie. have a higher VIP score), compared to SA
93	women. However, metabolite profiles are heterogenous mixtures of metabolites,
94	many of which are strongly correlated and may depend on other metabolites to
95	exhibit an effect. In light of this, multivariate approaches that assess all variables

8

simultaneously along with their inter-variable correlations (24) can be used to identify
(i) patterns of uncorrelated metabolites that associate with GDM risk, and (ii) cardinal
metabolites that independently associate with GDM risk. Therefore, this study aims
to build upon existing work by applying multivariate statistical techniques within an
ethnically diverse population to (i) determine underlining metabolite patterns that
correlate with GDM, (ii) identify ethnic-specific metabolic drivers of GDM risk.

102 Materials and Methods

103 i. Population Characteristics

104 The BiB cohort was established to examine determinants of health from pregnancy 105 and childhood into adulthood in an ethnically diverse region in the north of England 106 (25). Between 2007 and 2010, BiB recruited 12,453 women (26-28 weeks' gestation, 107 mean maternal age 27.8), collecting baseline data on 13,776 pregnancies and 108 13,858 births, with 45% of the cohort of SA origin (25, 26). BiB aimed to recruit all 109 mothers giving birth at the Bradford Royal Infirmary, the largest hospital within 110 Bradford. Bradford is a northern English city with high levels of deprivation and a 111 large SA population, the majority of which have Pakistani ancestry. All women were 112 invited to partake in an oral glucose tolerance test (OGTT) for GDM diagnosis at 113 approximately 26-28 weeks during their standard antennal care. Almost all UK 114 citizens utilize the NHS for antenatal care.

115

116 Of these, 11,480 women provided blood samples for metabolite analyses during the

same visit as their OGTT. Written consent was gained from all participants and

118 ethical approval was granted by the Bradford Research Ethnics Committee

119 (ref07/H1302/112)(25).

9

120 ii. Blood Metabolite Analysis

121 Full details of venous blood sample collection, preparation, metabolite quantification

and validation have previously been described in detail (1). In brief, fasted blood

- samples were taken at the Bradford Royal Infirmary by trained phlebotomists,
- 124 processed within 2.5 hours and stored at -80°C in the absence of freeze-thaw cycles.
- 125 (27) Samples were processed using a high-throughput automated NMR platform and
- have previously been validated (Nightingale Health©; Helsinki, Finland). Metabolite
- 127 values expressed as a percentage or ratio were excluded to minimize redundancy,
- resulting in a panel of 146 metabolite values expressed in absolute quantitative
- measures. This panel comprised measures of 97 lipoproteins, 9 amino acids, 2

apolipoproteins, 9 cholesterols, 8 fatty acids, 8 glycerides and phospholipids, 4

131 glycolysis-related metabolites, 2 ketone bodies, 3 measures of fluid balance and

132 inflammation, and 3 measures of the mean lipoprotein particle diameter

133 (Supplemental S1).

134 iii. Participant Selection

135 Of the 11,480 blood samples analyzed for metabolites, 54 samples were excluded 136 because they failed one of five Nightingale© guality control measures (low glucose, 137 high lactate, high pyruvate, low protein concentration and plasma samples). Of the 138 11,426 available samples, \sim 3% of mothers were missing \geq 1 metabolite values. The 139 structure of missing metabolite data was assessed via the visualization and 140 imputation of missing values (VIM) package within R (28) and multiple 141 correspondence analysis (MCA). There was no evidence that the missing metabolite 142 data occurred in a non-random pattern. It was therefore deemed appropriate to 143 impute missing values. Optimized multiple imputation with iterative principal 144 component analysis (PCA; 100 simulations, K-fold cross validation) based upon the

10

145 minimization of mean square error of prediction (MSEP) was performed using the 146 missMDA package (29). A sensitivity analysis was performed to test the effect of 147 mothers with higher rates of missingness (\geq 3% missing metabolite values) on 148 imputation. No detectable difference in imputation quality was noticed. As such, the 149 metabolite data of all available 11,426 maternal samples were included for 150 imputation. 151 Imputed metabolite data were combined with descriptive BiB reported 152 characteristics, including participant's ethnicity, age moved to UK (if born abroad)

153 GDM status, gestational age at sample collection (obtained from obstetric records),

154 history of diabetes, age, BMI, smoking status, parity and whether they were carrying

a singleton/multiple pregnancy. Length of residence was calculated by subtracting

the age the mother moved to the UK from maternal age. When an individual was

born within the UK, length of residency was taken to be mothers age.

158

159 All women were recruited prior to their scheduled GDM assessment (mean 160 gestational age 26.1 weeks), and prior to the 28th week of pregnancy. GDM was 161 diagnosed using a modified version of the World Health Organization criteria (1, 25). 162 Using this criteria, a women was diagnosed with GDM if either their fasting glucose 163 concentration exceed \geq 6.1 mmol/L or if 2-hour post-load glucose concentrations 164 was \geq 7.8 mmol/L following a 75g oral glucose tolerance test (OGTT). The OGTT 165 was completed in the morning following an overnight fast and involved the 166 consumption of a standard solution over a 5-minute period containing the equivalent 167 of 75g of anhydrous glucose (30). Following a GDM diagnosis all SA and WE 168 mothers receive the same standardised care following a GDM diagnosis. Initially 169 GDM management involves referral to a dietitian and the management of glucose

11

concentration through diet and increased exercise. If unsuccessful, managed by
metformin or insulin injections will be prescribed. Women with GDM will also be
offered additional antenatal appointments to monitor the health of both mother and
baby throughout the pregnancy. Irrespective of GDM status, basic nutritional
counselling is offered to all mothers as part of standard antenatal classes offered
throughout pregnancy by the UK National Health Services (NHS) (31).

176

177 Ethnicity was self-reported. If ethnicity was not collected, details were obtained from 178 primary care records along with information on parity and the number of registered 179 births. Maternal age was recorded at pregnancy booking (ie., the first routine 180 antenatal visit) and BMI was calculated using height measured at recruitment and 181 maternal weight recorded at the first antenatal visit. When examined as a categorical 182 variable, ethnic specific cut-offs were used to classify mothers into BMI groups (underweight: $\leq 18.5 \text{ kg/m}^2$ in WE and SAs, normal/healthy weight: $18.6-25 \text{ kg/m}^2$ in 183 WEs or 18.6-22.9 kg/m² in SAs, overweight: 25-29.9 kg/m² for WE or 23-27.4 kg/m² 184 for SA women; obese: > 30kg/m^2 for WE or >27.5kg/m² for SA women) (32). When 185 186 analysed as a binary variable, women were grouped as having a 'healthy' or 'high' 187 BMI if they were above/below the BMI cut-off for overweight status utilizing these 188 ethnic-specific cut offs. Smoking status was self-reported at baseline and during 189 pregnancy. Recruitment and the baseline assessment of covariates was the same in 190 both ethnic groups. Summary statistics for each variable were presented as a mean 191 and standard error (SE). Difference in baseline characteristics were calculated 192 between women with and without GDM for continuous variables via a Mann-Whitney 193 (MW) test, while differences for categorical variables were tested using Pearson's 194 Chi-squared test.

12

195	Participants whose samples were collected after GDM diagnosis (28 th week or later)
196	were excluded from the analysis as well as mothers with a history of diabetes.
197	Individuals who reported being of a South Asian origin other than Pakistani (SA)
198	were also excluded, due to the small sample size (therefore limited power) of other
199	South Asian ancestry groups. In total, 5,339 participants, 2,671 SAs (all of Pakistani
200	descent) and 2,688 White European (WE) women, were retained for analysis.
201	(Figure 1)
202	
203	Ethnicity was self-reported and the homogeneity of the WE group has been
204	confirmed in previous genetic analyses within BIB (33). 93.2% of the included WEs
205	were born in the British Isles (i.e., the UK, Republic of Ireland, Channel Islands or
206	Isle of Man), with the majority in England (91.4%). Of these women, 95.5% reported
207	that both of their parents were also born in the British Isles. Within the group of WE
208	women not born in the British Isles, 3.7% were born in Eastern Europe (Czech
209	Republic, Poland, Slovakia) with the remaining proportion reporting 'other' or
210	'unknown'. Within the SA population, 43.7% were born within the UK. Of the SA

women born in the UK, 93% reported that their mother was born in Pakistan (87.4%)

or India (5.6%) and 95% reported that their father was born in Pakistani (88.6%) or

India (6.7%). A small proportion did not know their mother's (1.4%) or father's (1.3%)

214 place of birth. Of the women born outside of the UK, the average age of immigration

215 to the UK was 18.8 yrs (IQR 18 - 23).

216

217 iv. Metabolite Discriminatory Analysis

Partial least squares discriminatory analysis (PLSDA) is a supervised dimensionality
reduction technique that uses all included variables to discriminate group data based

13

220	upon predefined outcome groups. Included variables are then ranked by the degree
221	to which they explain the variance between groups (i.e., GDM vs non-GDM). These
222	are known as variable importance in projection (VIPs), where VIPs ≥1 denote a
223	variable with good discriminatory quality and predictive ability (34, 35).
224	PLSDA allowed an overall assessment of the predictive capacity of
225	metabolites for GDM, in models with and without known GDM risk factors (i.e., BMI,
226	maternal age, parity, multiple pregnancy, and smoking status), with ethnicity added
227	to visually assess its effect on the model. Following this, both sets of PLSDA models
228	were performed within each ethnic group. To assess bi-directionality, models
229	predicting ethnicity were also executed within the overall population and GDM cases/
230	non-cases separately using the same criteria as above.
231	The optimum number of components to include within the model was selected
232	based upon the component's ability to significantly predict group membership within
233	the training (pR ² Y ≤0.05) and validation (pQ ² Y≤ 0.05) datasets (7-fold cross
234	validation, 'nipals' algorithm). When multiple components were significantly
235	predictive, the predictive component that best discriminated between groups (i.e.
236	maximization of outcome variance explained, R^2Y) with the minimal error (root mean
237	squared error of estimation (RMSEE)) was selected. Data were pareto scaled and
238	mean-centered prior to analysis. External validity was assessed via 7-fold cross
239	validation. PLSDA models were performed via the 'ropls' package within R (36).
240	When the size of the outcome groups differed by \geq 1% the larger group was
241	randomly sampled (n=20) to minimize error. VIPs were mean averaged and SEs
242	calculated across all significant iterations (pR ² Y \leq 0.05, pQ ² Y \leq 0.05) for each
243	metabolite following the removal of outlier VIPs, defined as 1.5 x interquartile range
244	of VIP values. Differences in the distribution of VIP values between both ethnicities

14

245 and case-status were assessed for significant iterations via a MW test; this was 246 possible because all comparisons were tested against the same panel of metabolite 247 measures. To assess the impact of smoking on PLSDA results, PLSDA models 248 predicting smoking in the overall study population were also performed. 249 250 iii. **Post-Hoc multivariate analyses** 251 BMI is a suspected mediator along the casual pathway that links metabolism and 252

253 this, the ethnic-specific impact of BMI on the metabolome and subsequent GDM

GDM, was a significant driver of GDM within SA women and WE women. To explore

254 diagnoses was investigated using sparse PLSDA (sPLSDA). sPLSDA is a

255 supervised multivariate technique with the ability to predict group membership in

256 multiclass problems (i.e., stratification by ethnicity, bodyweight, and GDM status) by

257 simultaneously performing and balancing variable selection with group classification

258 (37). Women were classified as 'healthy or 'overweight' based upon ethnic-specific

cut-offs (BMI \ge 25kg/m² for WE women and BMI \ge 23kg/m² for SA women), which is 259

260 the same approach used by the NHS (38). The analyses focussed on low-risk WE

261 (n= 872) and low-risk SA women (n= 864) — i.e., only women (i) in their first

262 pregnancy, (ii) that did not smoke during pregnancy, and (iii) were < 35 years of age

263 were included. This was done to prevent these covariates from overpowering the

264 models, and allowing the contributing roles of BMI on GDM to be more clearly

265 appreciated within and between each ethnic group.

266

267 Metabolites selected by sPLSDA in each comparison were fed into PLSDA models

268 (20 iterations) alongside highly correlated metabolites (Pearsons correlation

269 coefficient ≥0.9) in order determine metabolie values contributing to the separation of

15

270 the outcome groups whilst balancing dimensionality reduction and group 271 discrimination. PLSDA models were adjusted for maternal age (continuous), BMI 272 (continous), smoking status, partiy and multiple pregnancy such as before. 273 Differences in the distributions of metabolites within each group were also compared 274 by a MW test. 275 iii. Linear regression analyses for identified metabolite associations 276 Linear regression models investigating the relationship between post- oral OGTT 277 measures (fasting glucose and 2-hour post-OGTT) were performed on all metabolite 278 values identified as important (VIP≥1) in characterizing GDM status. Normality of 279 glucose measures and metabolite values were assessed using histograms and Q-Q 280 plots. Most metabolites (136/146) required normalization. Normality was most often 281 achieved by log transformation (59 metabolite values); however, in some cases 282 square-root and normal score transformation (NST) were implemented via the 283 'rcompanion' package(39). All glucose measures were log normalized. Known GDM 284 risk factors of maternal age (years), gestational age (days), parity, and smoking 285 status during pregnancy (yes/no), were initially including in the models. When 286 significant associations were observed between metabolite values and glucose in 287 this exploratory analysis (P<0.05), BMI was added to the models (initially as a 288 continuous and then as a binary variable utilizing ethnic-specific BMI cut-offs for 289 overweight status) to assess the role of early pregnancy BMI as a mediator of 290 metabolite-dysglycemia associations. Within SAs, a final additional adjustment of 291 length of residency within the UK was made to account for any effects of 292 acculturation.

16

293 Results

i. Population Characteristics

- ²⁹⁵ The mean age of participant was 26.7 years and had a mean BMI of 26 kg/m². WE
- women were significantly older and had higher BMIs compared to SA women (Table
- 1). Parity was significantly higher in SA women compared to WE women (P<0.001)
- and parity was only significantly higher in GDM cases compared to non-cases within
- 299 SA women (Table 1). Smoking during pregnancy was significantly more common in
- 300 WE women compared to SA women (25% vs 3%; P<0.001). No difference in
- 301 proportion of singleton pregnancies (>97%) was observed between WE women and
- 302 SA women. Alcohol intake was not assessed because it was reported by only 1% of
- 303 SA women. The mean time of sample collection was 187 gestational days.

304 ii. Primary Analysis

305 Metabolite Characterisation of GDM

In the 1st model, an overall analysis of the full cohort (i.e., both ethnic groups),

307 PLSDA explained 21.7% of the variation between the GDM and non-GDM groups

and confirmed maternal age and BMI as primary risk factors for GDM risk followed

309 by parity, smoking status, and having a non-singleton pregnancy as the primary

drivers of GDM (**Table 2**). In the full model, 7 metabolite values reported VIPs \geq 1,

including 4 fatty acid metabolite measures (total fatty acids, 18:2 linoleic acid, total

- 312 MUFA and total SFA), and one glycolysis related metabolite (lactate) (Figure 2).
- 313 Modelled independently, the PLSDA with only covariates explained 12.4% of the
- variation in GDM status and significantly predicted GDM status, whereas the model
- with only metabolites explained 13.5% of the variance in GDM but was non-
- 316 significant. The 2nd model, which included ethnicity as a covariate, accounted for

17

26.6% of the variation between the GDM and non-GDM groups. The same 6 metabolites we reported as predictors of GDM with an additional cholesterol metabolite measure (total esterified cholesterol). Notably, model 2 confirmed ethnicity (SA vs WE) as a major risk factor for GDM, after age and BMI. Modelled independently, 'ethnicity' and other covariates explained 15.2% of the variance in GDM status; therefore, the addition of metabolites into the model increased the amount of variance explained by over 11%.

324

325 Ethnically-stratified analysis of metabolites characterising GDM

In an ethnically stratified analysis (20 iterations), models only including metabolites

327 accounted for a median average of 6.5% of the variation in GDM status in SA

women and 5.8% of the variation in WE women in optimised models (ie.

329 minimisation RMSEE and maximisation of R²Y) although no model comprising

330 metabolites alone was significant. Conversely, models only including established

331 clinical risk factors (age, BMI, parity, smoking status and multiple pregnancy) were

significantly predictive (p- value $R^2 < 0.05$, $Q^2 < 0.05$) of GDM status and explained

13.3% of the variation in SAs 12.8% of the variation in WEs. The addition of

334 metabolites to these covariate models also resulted in the significant prediction of

335 GDM. These models resulted in 26% of the variance in GDM status in WE women

and 20% of the variance in SA women being accounted for, an increase of 13.6%

and 6.8% when compared to covariate models in WE and SA respectively. Following

adjustments for maternal age, parity, BMI, and smoking status, GDM could be

339 predicted within both ethnicites. Maternal age, parity and BMI were predictors of

GDM in both ethnicities (VIP≥1), with BMI the most important predictor of GDM in SA

341 women, while in WE women maternal age was most important predictor

18

342 (Supplementary table 1). Smoking was a predictor of GDM only in WE women. 343 After adjustment for confounders, 7 metabolite variables characterised GDM status 344 (VIP≥1) in both ethnicities (total fatty acids, total MUFA, total SFA, linoleic acid, 345 glycoprotein acetyls, lactate, and diameter of VLDL) (Figure 3, Supplementary 346 table 2). Of these metabolites, the VIPs of three (lactate, glycoprotein acetyls, and 347 linoleic acid) characterised GDM status comparatively well between ethnicites 348 (VIP≥1; MW P>0.05), whereas four metabolite measures (total fatty acids, total 349 MUFA, total SFA, and VLDL D) characterised GDM in both ethnic groups, but were 350 significantly stronger markers of GDM in WE women (VIP≥1: MW P<0.05 between 351 ethnicites). Additionally, alanine, glutamine, total cholesterol, total n-6 PUFA, total 352 PUFA, and citrate were markers (VIP \geq 1) of GDM status in WE women only. No 353 markers of GDM were specific to SA women. On average, the optimised models 354 explained 26% of the variance of GDM in WE women, and 20% of the variance in 355 SA, women (Supplementary table 3).

356 **Metabolites characterised by ethnicity**

357 To explore underlying metabolic profiles within each ethnic group, we identified 358 metabolites that most strongly distinguished WE women and SA women. In a 359 PLSDA including known GDM risk factors as covariates (maternal age, smoking 360 status, parity, BMI, and GDM status), 12 metabolic measures VIP≥1 in statistically significant models (models p-values $R^2 > 0.05$ and $Q^2 > 0.05$) and therefore were 361 362 believed to have characterised ethnicity in GDM and non-GDM women: total fatty 363 acids, serum cholesterol, SFA, MUFA, FAw6, esterified cholesterol, LA, LDL 364 cholesterol, remnant cholesterol, phosphatidylcholine and total cholesterol. 365 (Supplementary table 4).

366

19

- 367 Additionally, ethnicity was characterised by 6 metabolites values exclusivley in
- women diagnosed with GDM [i.e alanine, total fatty acids, linoleic acid (LA),
- 369 glycoprotein acetyls, lactate and diameter of VLDL] whilst 5 metabolites values were
- exclusive in those not diagnosed with GDM [i.e., apolipoprotein A1, remnant
- 371 choelsterol, docosahexanoic acid (DHA), and phosphatidylcholine]. An additional 9
- 372 metabolite values [ie., total serum cholesterol, LDL cholesterol, total esterfied
- 373 cholesterol, n-3 fatty acids, PUFA, MUFA, SFA, phosphatidylcholine and total
- 374 cholines] were predictive of ethnicity in both GDM cases and non-cases
- 375 (Supplementary figure 1).

376 iv. Post-Hoc Analyses

377 Characterisation of GDM in Low-Risk Women

- BMI was classifed as an important variable (VIP \geq 1) in the overall analysis and in
- both ethnic subgroup analyses. However, a greater mean VIP (± SE) was observed
- in SA women compared to WE women (VIP_{SA} = 7.06 \pm 0.22 vs. VIP_{WE} = 4.33 \pm 0.22;
- P<0.001) (Supplementary table 1) indicating that BMI may be a more important
- 382 predictor of GDM status within WEs. Indeed, healthy weight SA women who
- 383 developed GDM (SA_{Healthy-GDM}) presented the most distinct metabolic profile
- 384 (Receiver Operator Curve; ROC = 0.783), but were most similar to healthy WE
- 385 women who developed GDM (WE_{Healthy-GDM}; ROC = 0.691) (Supplementary figure
- 386 **2**). The reason for this shared and distinct pattern of metabolites in 'healthy' weight
- 387 women who developed GDM is unclear and many hypotheses are possible. One
- 388 hypothesis may be that the pattern is an artifact of their fetal programming. Adult
- offspring from GDM pregnancies are at increased risk of dysglycemia, diabetes, and

20

GDM that has been attributed to metabolic dysregulation, and early dysglycemia that
progresses in later life (40-43).

392	Future work in established cohorts that investigate trans-generational pregnancy
393	risks (such as Born in Bradford, Generation R, and Nutrigen) are integral to unravel
394	the source of this unique metabolic profile which distinguishes healthy weight GDM
395	cases of SA ancestry from non-cases, overweight SA cases, and WE cases (25, 44,
396	45). Due to the higher proportion of underweight mothers of SA ancestry, a
397	sensitivity analysis was performed where underweight mothers were removed
398	$(n_{removed} = 93, BMI \le 18.5 \text{ kg/m}^2)$ to determine if their profiles were unique. No
399	difference in the outcome was observed following the removal of these individuals.
400	Metabolites selected by sPLSDA in each comparison were fed into PLSDA
401	models (20 iterations) alongside highly correlated metabolites (Pearsons correlation
402	coefficient \geq 0.9) to identify key metabolic drivers of this separation (Supplementary
403	figure 3). Alanine, glutamine, and glycerol were important to distinguish healthy
404	weight SA women who developed GDM (SAC-N) from all others, whereas fatty acids
405	were important to distinguish SAC-N from other GDM cases. Interestingly, in healthy
406	women, aromatic and branched chain amino acids distinguished GDM and non-GDM
407	women between (but not within) ethnic groups. Glycerol distributions were
408	significantly different in all comparisons (MW <0.05).

409 Characterisation of GDM in low-risk women by BMI and ethnicity

410 Orthogonal partial least squares discriminant analysis (oPLSDA) is a supervised

- 411 multivariate technique that separates variation within each predictor variables based
- 412 upon its linear (correlated) and orthogonal (uncorrelated) association with the
- 413 outcome variable (46, 47). This can provide better separation along fewer
- 414 components when a large proportion of variance within the dataset does not directly

21

415 correlate with the outcome variable. Furthermore, through the creation of Shared and 416 Unique Structure (SUS) plots it is possible to determine shared and unique factors 417 separating the main group of interest (healthy weight SA cases, SAC-N) with the 418 two most relevant biological comparisons (healthy weight SA non-cases, SANC-N 419 and healthy weight WE cases, WEC-N). 420 No significant separation of the SAC-N vs SANC-N, SAC-N vs SAC-H and SAC-421 N vs WEC-N groups were identified via SUS plots with oPLSDA. Following the 422 inclusion of BMI and age within the models the SAC-N group was found to separate 423 from all other groups (**Supplementary figure 4**). BMI was the only variable found to 424 be responsible for this separation with a high magnitude and reliability. Pyruvate, L-425 HDL and XL-HDL had a small impact on the separation of the SAC-N group but with 426 a low reliability, as shown within SUS-plots. 427 Association between important metabolites and gestational dysglycemia 428 Overall, 8 of 146 metabolite measures were associated with fasting glucose or 2-429 hour post glucose (**Table 3**), all of which were identified as GDM predictors via 430 PLSDA or sPLSDA. The analysis in WE women demonstrated the greatest number

431 of associations between metabolite and glucose measures. Six metabolites

432 positively associated fasting glucose concentration (albumin, lactate, histidine,

433 apolipoprotein A1, HDLC and HDL2C), while one negatively associated with fasting

434 glucose (mean density of LDL) (**Supplementary table 5**, **Supplementary table 6**).

435 Only DHA associated with 2-hr post OGTT in WEs, where a 1 mmol/L increase in

436 DHA associated with a 0.20 mmol/L increase in 2-hour post glucose. In the analysis

437 of SA women, only albumin was associated with dysglycemia, where higher albumin

438 associated with lower concentration of fasting glucose and 2-hr post OGTT. In an

439 additional analysis, length of residency within the UK was added to the fully-adjusted

22

440	model to evaluate the role of UK acculturation as a modifier of the association
441	between albumin and postprandial glucose measures. In both models significant
442	associations were identified with albumin (P-value _{fasting} =0.031, β = -0.79, SE=0.37, P-
443	value _{2-hour} =0.028 β =-1.75 ,SE=0.80). Length of residency was not found to be a
444	significant variable in the model, but the magnitude of associations decreased
445	slightly following its inclusion (Supplementary table 5, Supplementary table 6). In
446	the ethnic-combined analysis, associations between albumin, lactate, and mean
447	diameter of LDL with fasting glucose retained significance. Adjusting for BMI as a
448	continuous or binary variable had no impact on the associations.
449	

450 Discussion

451 Using a prospective birth cohort with an equal proportion of WE and SA women, we 452 identified 7 metabolite measures that characterized GDM in both WE and SA women 453 - 4 of which were more predictive in WE women. These results agree with the 454 Omega cohort (78.5% non-Hispanic white; nested case-control; 46 cases, 47 455 controls) that highlighted a distinct metabolic profile at 16-weeks' gestation 456 (comprised of fatty acids, sugars, alcohols, amino acids and organic acids), 457 associated with future GDM diagnosis (48). Although the metabolite patterns 458 identified by the Omega study were not predictive, our predictive multivariate 459 analysis (and a previous univariate analyses) (1) found similar associations between 460 GDM and many of these metabolites (i.e., amino acids, glycolysis related 461 metabolites, and fatty acids), and offers further evidence of ethnic-specific 462 associations.

23

463	Given the overall elevated risk of GDM observed in SA women compared to
464	WE women, even at a healthy BMI (i.e., OR≈3) (49), and the role of ethnicity in
465	predicting GDM, in the present study, we sought to characterize distinct metabolic
466	profiles of SA and WE women. Of the 146 metabolite values tested, 7 were important
467	for stratifying GDM and non-GDM women in the overall population (lactate, mean
468	density of VLDL particles, total fatty acids, total MUFAs, 18:2 linoleic acid, total SFA
469	and esterified cholesterol). Following stratification by ethnicity, alanine, glutamine,
470	total serum cholesterol, n-6 fatty acids, PUFAs, and citrate distinguished GDM and
471	non-GDM in WE women whereas no metabolite values were predictive solely within
472	SA women.
473	Although no metabolite value identified solely within WE women was
474	associated with post-OGTT measures of glucose in <i>post-hoc</i> analyses, our evidence
475	agrees with previous work from (i) a small case-control study (26 T2Ds vs 7 controls)
476	that reported alanine, glutamine, and citrate to characterize GDM and controls, with
477	citrate being a key marker of diabetics with underlying complications (e.g., CVD)
478	(50), and (ii) a cohort study of 431 pregnant Chinese women (12-16 weeks'
479	gestation), where alanine and glutamine were associated with GDM (51).
480	Biologically, alanine, glutamine, and citrate are connected and could moderate
481	dysglycemia through their interaction with the tricarboxylic acid cycle (TCA) to
482	promote the formation of TCA intermediates, fatty acid synthesis, and modulate
483	glucagon and insulin secretion (52, 53). Taken together, it may be that alanine and
484	glutamine are more robust markers of dysglycemia, whereas citrate is a marker of
485	metabolic or physiologic stress in diabetic individuals — such as pregnancy. The role
486	of total cholesterol is uncertain as it is not convincingly associated with dysglycemia
487	(a meta-analysis of 73 observational studies found no association)(54), suggesting

24

that associations between total cholesterol and GDM are complex and/or subject toconfounding.

In the ethnic subgroup analyses, fatty acids were identified as the most important family (ie. $VIP \ge 1$) to characterize GDM status. In WE women and SA women respectively, 75% and 50% of the fatty acids included within the metabolite panel were considered 'important' to characterize GDM within WE women. Furthermore, in SA women fatty acids constituted more than half of all metabolites with a VIP ≥ 1 .

This reflects earlier work by Taylor *et al.* [1], which identified some evidence of ethnic specific associations between fatty acids and GDM, and agrees with molecular analyses that demonstrate that fatty acids alter insulin resistance and insulin secretion during pregnancy (55, 56).

500 Furthermore, fatty acids (total MUFAs, total n-3 PUFAs, total n-6 PUFAs, total 501 PUFAs, and DHA) were identified as key metabolic factors to distinguish healthy-502 weight SA and WE women who developed GDM. Interestingly, we highlighted 503 associations between n-6 PUFA and total PUFAs with GDM that were specific to WE 504 women. Given the equal sample sizes between groups, and that fatty acids were 505 important to characterize ethnicity, it is suggestive of ethnic differences in PUFA 506 metabolism (57-59) and a role in ethnic-associated GDM risk (57, 60, 61). Indeed, n6 507 PUFA-derived eicosanoids show discriminatory qualities between type-2 diabetics and controls with good accuracy ($R^2X = 0.824$, $R^2Y = 0.995$, $Q^2 = 0.779$) and were 508 509 identified as proposed mediators of dysglycemia within a Chinese population (62). 510 Longitudinal analyses to evaluate the association between changes in PUFA and

25

511 eicosanoids concentrations on dysglycemia during pregnancy are required to better512 understand this association.

513	The association between VLDL diameter and dysglycemia is supported by a
514	recent hypothesis linking insulin resistance, triglyceride synthesis, and increased
515	VLDL diameter (63, 64). Although we cannot disregard that VLDLs are sensitive to
516	level of fasting (65) (as our participants were subjected to prior to blood collection),
517	evidence also suggests that ethnic-specific genetic variants associate with ethnic-
518	specific differences in VLDL diameter (66). Although there has been less work on the
519	possible association between glycoprotein acetyls (a marker of systemic
520	inflammation) and GDM, and future work is required in this area
521	Lactate was one of the strongest predictors of GDM within both groups, in
522	agreement with evidence from a case-control study in China (n=12 GDM; n=10
523	controls) (67) and pathway analyses that propose lactate as a regulator of insulin
524	resistance and a marker metabolic syndrome severity (68, 69). Post-hoc analysis
525	demonstrated no association between glycoprotein acetyls and glucose
526	concerntrations, while lactate and mean diameter of VLDL were associated with
527	fasting glucose in WE women but not SA women. The multi-ethnic HAPO cohort
528	demonstrated a similar ethnic-specific association between lactate and fasting
529	glucose within individuals of Northern European ancestry but not minority ethnic
530	groups (48, 70, 71).
531	Of the numerous fatty acid measures that were associated with GDM, only

532 DHA was associated with a post-OGTT measures of glucose and only in WE

women. Overall, DHA is considered a protective metabolite against insulin resistance

534 (e.g., HOMA-IR); however, recent evidence suggests high heterogeneity (56, 72, 73).

26

535	As we did, researchers investigating the Camden pregnancy cohort (n=1,368)
536	reported a significant positive linear association between DHA and HOMA-IR (0.303
537	\pm 0.152 per unit DHA %; P<0.05) (56), while conversely, the DOMINO trial (n=1990
538	pregnant women) reported no difference in 1-hr post-OGTT glucose concentrations
539	between DHA supplemented mothers and controls (74). The reason for such
540	discrepancies is unclear but may be that n-3 PUFAs (such as DHA) require
541	interactions with other metabolites (e.g., Vitamin D) (75) to impart an effect,
542	concentrations of which vary considerably between populations, seasons, and
543	geographic region (76-78).
544	The study aimed to increase and test generalizability of results within a
545	diverse population; however, our results may not be generalizable across other
546	ethnic groups or geographic regions. Nonetheless, this study has four main
547	limitations. Firstly, samples were taken at a single time point before 28 weeks
548	gestation, therefore (i) we were unable to account for differences in fasting duration
549	and diurnal variation; and (ii) our results are not generalizable across the full-term of
550	pregnancy. Secondly, as with all observational studies, the effect of confounding
551	cannot be disregarded and causality cannot be inferred. Despite this, this is the first
552	study to use a panel of multivariate statistical techniques to characterize GDM within
553	a large prospective cohort with an equal representation of WE women and women
554	from a non-WE population, meaning that statistical power to measure the same
555	effect size is comparable between groups. Thirdly, the biological validity of the
556	identified metabolites was tested and many correlated with postprandial glucose
557	measures; and although confounding cannot be eliminated, all models included
558	known GDM confounders and modelling characterizing the overall metabolic

559 differences between ethnicities were also performed to test whether differences in

27

564	GDM risk.
563	are needed evaluate the presence of a moderating effect of diet on metabolism and
562	was not available for our analysis. Future work with comprehensive dietary records
561	diet is a contributor to metabolite concentrations, but comprehensive dietary data
560	metabolite profiles were found between ethnicities in relation to GDM status. Finally,

565 Conclusion

- 566 In conclusion, this study has identified unique and shared metabolic profiles
- that characterize GDM in WE and SA women. Future work exploring the moderating
- role of lifestyle on the metabolome and the underlying biological mechanisms driving
- the identified associations will provide a better understanding of the etiological
- 570 factors responsible for the heightened level of GDM risk experienced by SA women
- and shed light on improved prevention strategies
- 572

573 Acknowledgements

Born in Bradford (BiB) is only possible because of the enthusiasm and commitment
of the children and parents in BiB. We are grateful to all the participants, health
professionals, schools and researchers who have made Born in Bradford happen

References

1. Taylor K, Ferreira DLS, West J, Yang T, Caputo M, Lawlor DA. Differences in Pregnancy Metabolic Profiles and Their Determinants between White European and South Asian Women: Findings from the Born in Bradford Cohort. Metabolites. 2019;9(9).

2. Zeng Z, Liu F, Li S. Metabolic Adaptations in Pregnancy: A Review. Ann Nutr Metab. 2017;70(1):59-65.

3. Egan AM, Dow ML, Vella A. A Review of the Pathophysiology and Management of Diabetes in Pregnancy. Mayo Clin Proc. 2020;95(12):2734-46.

4. Chen Q, Francis E, Hu G, Chen L. Metabolomic profiling of women with gestational diabetes mellitus and their offspring: Review of metabolomics studies. J Diabetes Complications. 2018;32(5):512-23.

5. McIntyre HD, Catalano P, Zhang C, Desoye G, Mathiesen ER, Damm P. Gestational diabetes mellitus. Nat Rev Dis Primers. 2019;5(1):47.

6. Behboudi-Gandevani S, Amiri M, Bidhendi Yarandi R, Ramezani Tehrani F. The impact of diagnostic criteria for gestational diabetes on its prevalence: a systematic review and meta-analysis. Diabetol Metab Syndr. 2019;11:11.

7. Zhu Y, Zhang C. Prevalence of Gestational Diabetes and Risk of Progression to Type 2 Diabetes: a Global Perspective. Curr Diab Rep. 2016;16(1):7.

8. Saravanan P, Magee LA, Banerjee A, Coleman MA, Von Dadelszen P, Denison F, Farmer A, Finer S, Fox-Rushby J, Holt R, et al. Gestational diabetes: opportunities for improving maternal and child health. The Lancet Diabetes & Endocrinology. 2020;8(9):793-800.

9. Mijatovic-Vukas J, Capling L, Cheng S, Stamatakis E, Louie J, Cheung NW, Markovic T, Ross G, Senior A, Brand-Miller JC, et al. Associations of Diet and Physical Activity with Risk for Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis. Nutrients. 2018;10(6):698.

 American Diabetes A. 14. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020;43(Supplement 1):S183.

11. NICE. Diabetes in pregnancy: management from preconception to the postnatal period 2021 [updated 16th December 2020. Available from:

https://www.nice.org.uk/guidance/ng3/chapter/Recommendations#preconceptionplanning-and-care.

12. de Seymour J, Chia A, Colega M, Jones B, McKenzie E, Shirong C, Godfrey K, Kwek K, Saw S-M, Conlon C, et al. Maternal Dietary Patterns and Gestational Diabetes Mellitus in a Multi-Ethnic Asian Cohort: The GUSTO Study. Nutrients. 2016;8(9):574.

13. Zulyniak MA, Souza RJD, Shaikh M, Desai D, Lefebvre DL, Gupta M, Wilson J, Wahi G, Subbarao P, Becker AB, et al. Does the impact of a plant-based diet during pregnancy on birth weight differ by ethnicity ? A dietary pattern analysis from a prospective Canadian birth cohort alliance. BMJ Open. 2017;7.

14. Fuller H, Moore JB, Iles MM, Zulyniak MA. Ethnic-specific associations between dietary consumption and gestational diabetes mellitus incidence: a meta-analysis. PLOS Global Public Health. 2022.

15. Zulyniak MA, de Souza RJ, Shaikh M, Ramasundarahettige C, Tam K, William N, Desai D, Lefebvre DL, Gupta M, Subbarao P. Ethnic differences in maternal diet in pregnancy and infant eczema. PLoS One. 2020;15(5):e0232170.

16. Wang Q, Wurtz P, Auro K, Makinen VP, Kangas AJ, Soininen P, Tiainen M, Tynkkynen T, Jokelainen J, Santalahti K, et al. Metabolic profiling of pregnancy: cross-sectional and longitudinal evidence. BMC Med. 2016;14(1):205.

17. Law KP, Zhang H. The pathogenesis and pathophysiology of gestational diabetes mellitus: Deductions from a three-part longitudinal metabolomics study in China. Clin Chim Acta. 2017;468:60-70.

18. McCabe CF, Perng W. Metabolomics of Diabetes in Pregnancy. Curr Diab Rep. 2017;17(8):57.

19. Mitro SD, Wu J, Rahman ML, Cao Y, Zhu Y, Chen Z, Chen L, Li M, Hinkle SN, Bremer AA, et al. Longitudinal Plasma Metabolomics Profile in Pregnancy—A Study in an Ethnically Diverse U.S. Pregnancy Cohort. Nutrients. 2021;13(9):3080.

20. Farrar D, Fairley L, Santorelli G, Tuffnell D, Sheldon TA, Wright J, van Overveld L, Lawlor DA. Association between hyperglycaemia and adverse perinatal outcomes in south Asian and white British women: analysis of data from the Born in Bradford cohort. The Lancet Diabetes & Endocrinology. 2015;3(10):795-804.

21. NHS. Overview Gestational Diabetes <u>www.NHS.co.uk</u>: NHS; 2019 [updated 06/08/2019. Available from: <u>https://www.nhs.uk/conditions/gestational-diabetes/</u>.

22. Schaefer-Graf U, Napoli A, Nolan CJ, Diabetic Pregnancy Study G. Diabetes in pregnancy: a new decade of challenges ahead. Diabetologia. 2018;61(5):1012-21.

23. Mao X, Chen X, Chen C, Zhang H, Law KP. Metabolomics in gestational diabetes. Clin Chim Acta. 2017;475:116-27.

24. Saccenti E, Hoefsloot HCJ, Smilde AK, Westerhuis JA, Hendriks MMWB. Reflections on univariate and multivariate analysis of metabolomics data. Metabolomics. 2013;10(3):361-74.

25. Wright J, Small N, Raynor P, Tuffnell D, Bhopal R, Cameron N, Fairley L, Lawlor DA, Parslow R, Petherick ES, et al. Cohort Profile: the Born in Bradford multi-ethnic family cohort study. Int J Epidemiol. 2013;42(4):978-91.

26. Bird PK, McEachan RRC, Mon-Williams M, Small N, West J, Whincup P, Wright J, Andrews E, Barber SE, Hill LJB, et al. Growing up in Bradford: protocol for the age 7-11 follow up of the Born in Bradford birth cohort. BMC Public Health. 2019;19(1):939-.

27. Taylor K, McBride N, J Goulding N, Burrows K, Mason D, Pembrey L, Yang T, Azad R, Wright J, A Lawlor D. Metabolomics datasets in the Born in Bradford cohort [version 2; peer review: 1 approved, 1 approved with reservations]. Wellcome Open Research. 2021;5(264).

28. Alexander Kowarik MT. Imputation with the R Package VIM. Journal of Statistical Software. 2016;74(7):1-16.

29. Josse J, Husson F. missMDA: A Package for Handling Missing Values in Multivariate Data Analysis. Journal of Statistical Software. 2016;70(1).

30. Lawlor DA, West J, Fairley L, Nelson SM, Bhopal RS, Tuffnell D, Freeman DJ, Wright J, Whitelaw DC, Sattar N. Pregnancy glycaemia and cord-blood levels of insulin and leptin in Pakistani and white British mother–offspring pairs: findings from a prospective pregnancy cohort. Diabetologia. 2014;57(12):2492-500.

31. NHS. Antental Classes <u>www.NHS.co.uk</u>: NHS; 2021 [updated 17/03/2021. Available from: <u>https://www.nhs.uk/pregnancy/labour-and-birth/preparing-for-the-birth/antenatal-classes/</u>.

32. WHO. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. The Lancet. 2004;363(9403):157-63.

33. Arciero E, Dogra SA, Malawsky DS, Mezzavilla M, Tsismentzoglou T, Huang QQ, Hunt KA, Mason D, Sharif SM, van Heel DA, et al. Fine-scale population structure and demographic history of British Pakistanis. Nature Communications. 2021;12(1):7189.

34. Perreault M, Zulyniak MA, Badoud F, Stephenson S, Badawi A, Buchholz A, Mutch DM. A distinct fatty acid profile underlies the reduced inflammatory state of metabolically healthy obese individuals. PLoS One. 2014;9(2):e88539-e.

35. Badoud F, Lam KP, DiBattista A, Perreault M, Zulyniak MA, Cattrysse B, Stephenson S, Britz-McKibbin P, Mutch DM. Serum and Adipose Tissue Amino Acid Homeostasis in the Metabolically Healthy Obese. Journal of Proteome Research. 2014;13(7):3455-66.

36. Thevenot EA, Roux A, Xu Y, Ezan E, Junot C. Analysis of the Human Adult Urinary Metabolome Variations with Age, Body Mass Index, and Gender by Implementing a Comprehensive Workflow for Univariate and OPLS Statistical Analyses. J Proteome Res. 2015;14(8):3322-35.

37. Lê Cao K-A, Boitard S, Besse P. Sparse PLS discriminant analysis: biologically relevant feature selection and graphical displays for multiclass problems. BMC Bioinformatics. 2011;12(1):253.

38. NHS. BMI Healthy Weight Calculator: NHS; 2018 [updated 5/11/2018. Available from: <u>https://www.nhs.uk/live-well/healthy-weight/bmi-calculator/</u>.

39. Mangiafico S. rcompanion: Functions to Support Extension Education Program Evaluation. R package version 2.4.1. ed2021.

40. Egeland G, Meltzer SJ. Following in mother's footsteps? Mother-daughter risks for insulin resistance and cardiovascular disease 15 years after gestational diabetes. Diabetic Medicine. 2010;27(3):257-65.

41. Clausen TD, Mathiesen ER, Hansen T, Pedersen O, Jensen DM, Lauenborg J, Schmidt L, Damm P. Overweight and the metabolic syndrome in adult offspring of women with diettreated gestational diabetes mellitus or type 1 diabetes. The Journal of Clinical Endocrinology & Metabolism. 2009;94(7):2464-70.

42. McLean M, Chipps D, Cheung NW. Mother to child transmission of diabetes mellitus: does gestational diabetes program Type 2 diabetes in the next generation? Diabetic Medicine. 2006;23(11):1213-5.

43. Anand SS, Gupta M, Teo KK, Schulze KM, Desai D, Abdalla N, Zulyniak M, de Souza R, Wahi G, Shaikh M. Causes and consequences of gestational diabetes in South Asians living in Canada: results from a prospective cohort study. CMAJ open. 2017;5(3):E604.

44. Jaddoe VW, Mackenbach JP, Moll HA, Steegers EA, Tiemeier H, Verhulst FC, Witteman JC, Hofman A. The Generation R Study: Design and cohort profile. Eur J Epidemiol. 2006;21(6):475-84.

45. de Souza RJ, Zulyniak MA, Desai D, Shaikh MR, Campbell NC, Lefebvre DL, Gupta M, Wilson J, Wahi G, Atkinson SA, et al. Harmonization of Food-Frequency Questionnaires and Dietary Pattern Analysis in 4 Ethnically Diverse Birth Cohorts. The Journal of nutrition. 2016;146(11):2343-50.

46. Worley B, Powers R. Multivariate Analysis in Metabolomics. Curr Metabolomics. 2013;1(1):92-107.

47. Blasco H, Blaszczynski J, Billaut JC, Nadal-Desbarats L, Pradat PF, Devos D, Moreau C, Andres CR, Emond P, Corcia P, et al. Comparative analysis of targeted metabolomics:

dominance-based rough set approach versus orthogonal partial least square-discriminant analysis. J Biomed Inform. 2015;53:291-9.

48. Enquobahrie DA, Denis M, Tadesse MG, Gelaye B, Ressom HW, Williams MA. Maternal Early Pregnancy Serum Metabolites and Risk of Gestational Diabetes Mellitus. J Clin Endocrinol Metab. 2015;100(11):4348-56.

49. Makgoba M, Savvidou M, Steer P. An analysis of the interrelationship between maternal age, body mass index and racial origin in the development of gestational diabetes mellitus. BJOG: An International Journal of Obstetrics & Gynaecology. 2012;119(3):276-82.

50. Del Coco L, Vergara D, De Matteis S, Mensa E, Sabbatinelli J, Prattichizzo F, Bonfigli AR, Storci G, Bravaccini S, Pirini F, et al. NMR-Based Metabolomic Approach Tracks Potential Serum Biomarkers of Disease Progression in Patients with Type 2 Diabetes Mellitus. J Clin Med. 2019;8(5).

51. Jiang R, Wu S, Fang C, Wang C, Yang Y, Liu C, Hu J, Huang Y. Amino acids levels in early pregnancy predict subsequent gestational diabetes. J Diabetes. 2020;12(7):503-11.

52. Newsholme P, Brennan L, Rubi B, Maechler P. New insights into amino acid metabolism, beta-cell function and diabetes. Clin Sci (Lond). 2005;108(3):185-94.

53. Haber EP, Procopio J, Carvalho CR, Carpinelli AR, Newsholme P, Curi R. New insights into fatty acid modulation of pancreatic beta-cell function. Int Rev Cytol. 2006;248:1-41.

54. Ryckman KK, Spracklen CN, Smith CJ, Robinson JG, Saftlas AF. Maternal lipid levels during pregnancy and gestational diabetes: a systematic review and meta-analysis. BJOG. 2015;122(5):643-51.

55. Villafan-Bernal JR, Acevedo-Alba M, Reyes-Pavon R, Diaz-Parra GA, Lip-Sosa DL, Vazquez-Delfin HI, Hernandez-Muñoz M, Bravo-Aguirre DE, Figueras F, Martinez-Portilla RJ. Plasma Levels of Free Fatty Acids in Women with Gestational Diabetes and Its Intrinsic and Extrinsic Determinants: Systematic Review and Meta-Analysis. J Diabetes Res. 2019;2019:7098470-.

56. Chen X, Stein TP, Steer RA, Scholl TO. Individual free fatty acids have unique associations with inflammatory biomarkers, insulin resistance and insulin secretion in healthy and gestational diabetic pregnant women. BMJ Open Diabetes Res Care. 2019;7(1):e000632.

57. Gray RG, Kousta E, McCarthy MI, Godsland IF, Venkatesan S, Anyaoku V, Johnston DG. Ethnic variation in the activity of lipid desaturases and their relationships with cardiovascular risk factors in control women and an at-risk group with previous gestational diabetes mellitus: a cross-sectional study. Lipids Health Dis. 2013;12:25-.

58. Benedetti S, Al-Tannak NF, Alzharani M, Moir HJ, Stensel DJ, Thackray AE, Naughton DP, Dorak MT, Spendiff O, Hill N. Plasma free fatty acids metabolic profile with LC-MS and appetite-related hormones in South Asian and White European men in relation to adiposity, physical activity and cardiorespiratory fitness: a cross-sectional study. Metabolites. 2019;9(4):71.

59. Ralston JC, Zulyniak MA, Nielsen DE, Clarke S, Badawi A, El-Sohemy A, Ma DW, Mutch DM. Ethnic-and sex-specific associations between plasma fatty acids and markers of insulin resistance in healthy young adults. Nutrition & metabolism. 2013;10(1):42.

60. Yuen L, Wong VW, Simmons D, Simmons D. Ethnic Disparities in Gestational Diabetes. Current Diabetes Report. 2018;18(68).

61. Cheung NW. The influence of ethnicity on the development of type 2 diabetes mellitus in women with gestational diabetes: a prospective study and review of the literature. ISRN endocrinology. 2012;2012.

62. Xia F, He C, Ren M, Xu F-G, Wan J-B. Quantitative profiling of eicosanoids derived from n-6 and n-3 polyunsaturated fatty acids by twin derivatization strategy combined with LC-MS/MS in patients with type 2 diabetes mellitus. Analytica Chimica Acta. 2020;1120:24-35.

63. Zhao H, Li H, Chung ACK, Xiang L, Li X, Zheng Y, Luan H, Zhu L, Liu W, Peng Y, et al. Large-Scale Longitudinal Metabolomics Study Reveals Different Trimester-Specific Alterations of Metabolites in Relation to Gestational Diabetes Mellitus. J Proteome Res. 2019;18(1):292-300.

64. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004;27(6):1496-504.

65. Nordestgaard BG. A Test in Context: Lipid Profile, Fasting Versus Nonfasting. Journal of the American College of Cardiology. 2017;70(13):1637-46.

66. Frazier-Wood AC, Manichaikul A, Aslibekyan S, Borecki IB, Goff DC, Hopkins PN, Lai C-Q, Ordovas JM, Post WS, Rich SS, et al. Genetic variants associated with VLDL, LDL and HDL particle size differ with race/ethnicity. Human Genetics. 2013;132(4):405-13.

67. Liu T, Li J, Xu F, Wang M, Ding S, Xu H, Dong F. Comprehensive analysis of serum metabolites in gestational diabetes mellitus by UPLC/Q-TOF-MS. Anal Bioanal Chem. 2016;408(4):1125-35.

68. Wu Y, Dong Y, Atefi M, Liu Y, Elshimali Y, Vadgama JV. Lactate, a Neglected Factor for Diabetes and Cancer Interaction. Mediators Inflamm. 2016;2016:6456018.

69. Jones TE, Pories WJ, Houmard JA, Tanner CJ, Zheng D, Zou K, Coen PM, Goodpaster BH, Kraus WE, Dohm GL. Plasma lactate as a marker of metabolic health: Implications of elevated lactate for impairment of aerobic metabolism in the metabolic syndrome. Surgery. 2019;166(5):861-6.

70. Jacob S, Nodzenski M, Reisetter AC, Bain JR, Muehlbauer MJ, Stevens RD, Ilkayeva OR, Lowe LP, Metzger BE, Newgard CB, et al. Targeted Metabolomics Demonstrates Distinct and Overlapping Maternal Metabolites Associated With BMI, Glucose, and Insulin Sensitivity During Pregnancy Across Four Ancestry Groups. Diabetes care. 2017;40(7):911-9.

71. Chen YD VB, Reaven GM. Plasma lactate concentration in obesity and type 2 diabetes. Diabete & Metabolisme. 1993;19(4).

72. Zhu Y, Li M, Rahman ML, Hinkle SN, Wu J, Weir NL, Lin Y, Yang H, Tsai MY, Ferrara A, et al. Plasma phospholipid n-3 and n-6 polyunsaturated fatty acids in relation to cardiometabolic markers and gestational diabetes: A longitudinal study within the prospective NICHD Fetal Growth Studies. PLoS Med. 2019;16(9):e1002910.

73. Brown TJ, Brainard J, Song F, Wang X, Abdelhamid A, Hooper L, Group P. Omega-3, omega-6, and total dietary polyunsaturated fat for prevention and treatment of type 2 diabetes mellitus: systematic review and meta-analysis of randomised controlled trials. BMJ. 2019;366:14697.

74. Zhou SJ, Yelland L, McPhee AJ, Quinlivan J, Gibson RA, Makrides M. Fish-oil supplementation in pregnancy does not reduce the risk of gestational diabetes or preeclampsia. Am J Clin Nutr. 2012;95(6):1378-84.

75. Jamilian M, Samimi M, Ebrahimi FA, Hashemi T, Taghizadeh M, Razavi M, Sanami M, Asemi Z. The effects of vitamin D and omega-3 fatty acid co-supplementation on glycemic control and lipid concentrations in patients with gestational diabetes. J Clin Lipidol. 2017;11(2):459-68.

76. Darling AL, Hart KH, Macdonald HM, Horton K, Kang'ombe AR, Berry JL, Lanham-New SA. Vitamin D deficiency in UK South Asian Women of childbearing age: a comparative longitudinal investigation with UK Caucasian women. Osteoporos Int. 2013;24(2):477-88.

77. Sedhain A, Bhattarai GR, Yadav SR, Pandey BR, Pant TP. Geographic and Seasonal Variation of Vitamin D: A Retrospective Study in Two Centers of Nepal. J Nepal Health Res Counc. 2020;18(1):103-7.

78. Lagunova Z, Porojnicu AC, Lindberg F, Hexeberg S, Moan J. The dependency of vitamin D status on body mass index, gender, age and season. Anticancer Res. 2009;29(9):3713-20.

Table 1: Population Characteristics at < 28 weeks' gestation (mean gestational age 26.7 weeks) from the Born in Bradford

	Overall	White European			South Asian				White European vs South Asian P-values			
	Total (n=5339)	Total (n=2668)	GDM (n=128)	Non-GDM (n=2540)	P- value	Total (n=2,671)	GDM (n=286)	Non-GDM (n=2385)	P- value	Overall (n=5339)	GDM (n=414)	Non-GDM (n=4925)
Age (years) Mothers weight at baseline	27.3 (0.08) 68.8 (0.2)	26.7 (0.1) 72.0 (0.3)	30 (0.5) 76.8 (1.6)	26.5 (0.1) 71.8 (0.3)	< 0.001 0.002	25.7 (0.1) 65.5 (0.3)	30.6 (0.3) 72.3 (0.9)	27.6 (0.1) 64.7 (0.3)	< 0.001 < 0.001	< 0.001 < 0.001	0.29 0.03	< 0.001 < 0.001
Assessment (kg) Mothers' height (cm) BMI ¹	162 (0.09)	164.3 (0.1)	163.8 (0.5)	164.3 (0.1)	0.47	159.7 (0.1)	158.1 (0.3)	159.9 (0.1)	< 0.001	< 0.001	< 0.001	< 0.001
mean (kg/m²) underweight or normal	26.2 (0.08) 2198 (41.2)	26.7 (0.1) 1254 (47)	28.5 (0.5) 47 (36.7%)	26.6 (0.1) 1207 (47.5%)	< 0.001 0.02	25.7 (0.1) 944 (35.3)	28.9 (0.4) 46 (16.1)	25.3 (0.1) 898 (37.7)	< 0.001 < 0.001	< 0.001 < 0.001	0.49 < 0.001	< 0.001 < 0.001
overweight or obese Parity	3141 (58.8)	1414 (53)	81 (63.3%)	1333 (52.5%)	0.47	1727 (64.7)	240 (83.9)	1487 (62.3)	< 0.001	< 0.001	< 0.001	< 0.001
0	2311 (43.2) 1508	1394 (52.2) 813 (30)	73 (57) 39 (30.5)	1321 (52) 774 (30.5)		917 (34.3) 695 (26)	82 (28.7) 49 (17.1)	835 (36.5) 646 (28.3)				
2 ≥ 3	(28.2) 813 (15.2) 707 (13.2)	293 (11) 168 (6.3)	11 (8.6) 5 (3.9)	282 (11.1) 163 (10.4)	0.04	520 (19.5) 539 (20.2)	57 (19.9) 98 (34.3)	463 (20.3) 441 (14.9)	0.40	0.70	0.00	0.75
Singleton pregnancy (%) Smoked during	5274 (98.8) 958 (17.9)	2634 (98.7) 870	123 (96.1) 25 (19.5)	2511 (98.9) 845 (33.3)	0.01	2640 (98.8) 88 (3.3)	280 (97.9) 12 (4.2)	2360 (99) 76 (3.2)	0.12 0.37	0.70 < 0.001	0.29 <0.001	0.75 < 0.001
pregnancy (%)	1	(32.0)										

¹ Summary table of population characteristics, expressed as a mean (SE) for continuous variables and counts (%) for categorical variables. Differences between women with and without GDM for continuous variables were tested using a Mann-Whitney test, while differences for categorical variables were tested using Pearson's Chi-squared test.

(BiB) cohort.²

² Body Mass Index (BMI) cut-offs: underweight, \leq 18.5 kg/m² in WE and SAs; normal weight, 18.6-25 kg/m² in WEs or 18.6-22.9 kg/m² in SAs; overweight, 25-29.9 kg/m² for WE or 23-27.4 kg/m² for SA women; obese, \geq 30kg/m² for WE or \geq 27.5kg/m² for SA women. SA, South Asian; WE, white European.

Variable	Model 1	Model 2
Age	6.4 (0.03)	5.9 (0.03)
BMI	5.4 (0.04)	5.1 (0.02)
Ethnicity	-	2.9 (0.02)
Parity	2.4 (0.01)	2.3 (0.01)
Smoking Status	1.9 (0.02)	1.7 (0.01)
Multiple Pregnancy	1.5 (0.01)	1.3 (0.009)
Lactate	1.5 (0.01)	1.2 (0.008)
VLDL_D	1.3 (0.01)	1.3 (0.01)
Total Fatty Acids	1.2 (0.01)	1.5 (0.01)
Total MUFA	1.2 (0.001)	1.2 (0.008)
18:2 Linoleic Acid	1.1 (0.01)	1.1 (0.004)
Total SFA	1.1 (0.01)	1.2 (0.007)
Esterified Cholesterol	-	1.0 (0.008)

Table 2: Key metabolite measures (VIP \geq 1) that discriminate women diagnosed as GDM from non-GDM women in Partial Least Squares Discriminatory Analysis (PLSDA).¹

¹ Variables of Importance in Projection (VIPs) scores [mean and (standard error)] across 20 PLSDA iterations discriminating between GDM (n=414) and non-GDM women (n=414). Model 1: Includes all metabolite measures plus BMI (continuous), maternal age (years), smoking status, parity and multiple pregnancy status. Model 2: Model 1 + ethnicity. GDM, Gestational Diabetes Mellitus; MUFA, total monounsaturated fatty acids; SFA, total saturated fatty acids; VLDL_D, mean diameter of very-low density lipoproteins.

 Table 3: Metabolite measures associated with dysglycemia in South Asian and

 white European pregnant women before 28 weeks' gestation (mean gestational

 age 26.7 weeks)¹

Dysglycemia (mmol/L)	Combined analyses of South Asian and White Europeans (n=5538)	South Asian (n=2671)	White European (n=2267)
	(1-0000)		
Fasting	Albumin (-) ²		Lactate (-)
glucose	Lactate (-)		Histidine (-)
	LDL_D (+)		ApoA1 (-)
			HDL-C (-)
			HDL2-C (-)
			LDL_D (+)
2-hour post glucose		Albumin (-)	DHA (+)

¹ Multivariable linear regression analysis was undertaken in the overall population of pregnant women of 2671 South Asians and 2667 White Europeans. Metabolites associated (P<0.05) with measures of fasting glucose or 2-hr post oral glucose tolerance test (OGTT) in the overall population or in ethnicspecific analyses are presented. All models included maternal age (years), gestational age (days), parity, BMI (continuous), and smoking status during pregnancy. No differences in association were identified when BMI was included within the model as a categorical variable.

² Direction of associations are presented in brackets — i.e. positive (+) or negative (-). ApoA1, Apolipoprotein A1; DHA, Docosahexaenoic acid; HDL-C, High-density lipoprotein cholesterol; HDL2-C, High-density lipoprotein-2 cholesterol; LDL_D, mean diameter of low-density lipoprotein.

38

Figure 1: Flow chart of study participants from the Born in Bradford (BiB) cohort included within this study.

Figure 2: Circular bar plot identifying key metabolites (VIP \ge 1) that distinguished 414 women with gestational diabetes mellitus (GDM) from 414 women without GDM.

Mean average VIP scores across 20 PLSDA model iterations (n_{cases} = 414). Bars represent standard errors (SEs). The PLSDA included maternal age (years), BMI (continuous), smoking status, parity, and multiple pregnancy status, and ethnicity. Red line denotes VIP cut-off of 1. Units mmol/L unless stated. GRM, Glycolysis Related Metabolites; LPS, Lipoprotein Particle Size; MUFA, total monounsaturated fatty acids; SFA, total saturated fatty acids; VLDL_D, mean diameter of very-low density lipoproteins.

Figure 3: Circular bar plot of ethnically stratified analyses identifying key metabolites (VIP \geq 1) that distinguished GDM women from non GDM women in South Asians (n_{cases}=286) 2and white Europeans (n_{cases}=128).

Mean average VIP scores across 20 PLSDA model iterations ($n_{casesSA} = 286$, $n_{casesWE}=128$). Bars represent standard errors (SEs). The PLSDA was run separately for SA (blue) and WE (red) women and included maternal age (years), BMI (continuous), smoking status, parity, and multiple pregnancy status. Red circular line denotes VIP cut-off of 1. No lipoproteins demonstrated a VIP >1 and were not included in the figure to preserve space. Units mmol/L unless stated. 18.2 LA, 18.2 Linoleic acid; GRM, Glycolysis Related Metabolites; LPS, Lipoprotein Particle Size;

MUFA, total monounsaturated fatty acids; SFA, total saturated fatty acids; Tot FA,

Total fatty acids; VLDL_D, mean diameter of very-low density lipoproteins.

nedRxiv preprint doi: https://doi.org/10.1101/2022.04.11.22273658; this version posted June 13, 2022. The copyright holder for this (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in per



Failed Nightingale © quality control test N = 54



